Lobbying Activity Report

2603-18596

Organization: Sandoz Canada Inc.
Associated registration: 2015-2603-12
Lobbying Activity date: 2022-05-02
Arranged a meeting: Yes
Posted date: 2022-05-18

In-house lobbyists who participated in the lobbying activity: Guillaume Lefevre
Catherine Rousseau
Senior Public Office Holders who were lobbied in this activity: Sue Bouma, Executive Director, Clinical Services&Evaluation
Pharamceutical, Laboratory&Blood Services, Provincial Health Services Authority

John Capelli, Executive Director, Pharmaceutical Policy, Legislation &Engagement
Pharmaceutical, Laboratory&Blood Services, Provincial Health Services Authority

Mariana Diacu, Excutive Director
Laboratory & Blood Services, Provincial Health Services Authority

Tijana Fazlagic, Executive Director, Therapeutic Assessment&Access
Pharmaceutical, Laboratory&Blood Services, Provincial Health Services Authority

Luba Kamenko, Assistant Director, Decision Support, Finance and Corporate Services
Pharmaceutical, Laboratory &Blood Services, Provincial Health Services Authority

Mitch Moneo, Assistant Deputy Minister
Pharmaceutical, Laboratory&Blood Services, Provincial Health Services Authority

Derek Tryan, Executive coordinator, Pharmaceutical, Laboratory &Blood Services
Pharmaceutical, Laboratory&Blood Services, Provincial Health Services Authority

Kelly Uyeno, Executive Director, Integrated Health Services Planning&Systems
Pharmaceutical, Laboratory&Blood Services, Provincial Health Services Authority
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Discuss matters related to public funding of pharmaceutical treatments that are developed, manufactured and supplied by Sandoz Canada Inc.
  • Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
  • Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
 Finances and Budgets, Health
Improve regulatory environment and utilization rates for generics and biosimilars.
  • Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
  • Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
 Finances and Budgets, Health
 
Senior officer who filed this Lobbying Activity Report: Michel Robidoux
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
Date Modified: